home / stock / prvl / prvl news

PRVL News and Press, Prevail Therapeutics Inc. From 08/05/20

Stock Information
Company Name: Prevail Therapeutics Inc.
Stock Symbol: PRVL
Market: NYSE
Website: prevailtherapeutics.com
Menu
PRVL PRVL Quote PRVL Short PRVL News PRVL Articles PRVL Message Board
Get PRVL Alerts

News, Short Squeeze, Breakout and More Instantly...
PRVL - Prevail Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that Asa Abeliovich, M.D., Ph.D., Founder and Chi...
PRVL - Prevail Therapeutics to Webcast Conference Call of Second Quarter 2020 Financial Results

NEW YORK, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the company will host a conference call and ...

PRVL - Prevail Therapeutics Granted Composition of Matter Patent for Experimental Gene Therapy Program PR006

NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc.  (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the United States Patent and Trademark ...

PRVL - Prevail Therapeutics to Highlight Multiple Gene Therapy Programs for Neurodegenerative Diseases at the Virtual 2020 Alzheimer's Association International Conference

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Overview of Planned Phase 1/2 PR006 PROCLAIM Clinical Trial for FTD-GRN Patients Company to Host a Panel Discuss...
PRVL - Prevail Therapeutics to Present at The Jefferies Virtual Global Healthcare Conference

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announc...

PRVL - Prevail Therapeutics to Participate in Fireside Chat at Chardan 4th Annual Genetic Medicines Manufacturing Summit

CEO, CTO to Discuss Company’s Manufacturing and CMC Strategy and Overall Industry Trends NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patient...

PRVL - Prevail Therapeutics EPS misses by $0.06

Prevail Therapeutics (NASDAQ: PRVL ): Q1 GAAP EPS of -$0.56 misses by $0.06 . More news on: Prevail Therapeutics Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

PRVL - Prevail Therapeutics Reports First Quarter 2020 Financial Results and Business Highlights

Phase 1/2 Trial of PR001 for Parkinson’s Disease with GBA1 Mutations Ongoing; Study Startup Activities Progressing for Phase 1/2 Trials of PR001 for Type 2 Neuronopathic   Gaucher Disease and PR006 for Frontotemporal Dementia with GRN Mutations Data Presentations Highl...

PRVL - Prevail Therapeutics to Present at Bank of America Global Research Virtual Health Care Conference 2020

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL) (“Prevail” or “the Company”), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announc...

PRVL - Prevail Therapeutics to Highlight Multiple CNS-Focused Gene Therapy Programs at 2020 American Society of Gene & Cell Therapy Annual Meeting

Preclinical Data Demonstrate Potential of Prevail’s AAV Gene Therapy Approach to Slow or Halt Progression in Multiple Neurodegenerative Diseases Company Provides Design Overview for Planned Phase 1/2 PR001 PROVIDE and PR006 PROCLAIM Clinical Trials NEW YORK, April 29, 2020 (...
Previous 10 Next 10